Lung Cancer
Adenoviral overexpression coupled with lab assays can uncover gene profiles
Published in Gene Therapy Weekly, December 4th, 2003
"The retinoblastoma gene family consisting of RB/p105, p107, and RB2/p130 cooperate to regulate cell-cycle progression through the G1 phase of the cell cycle. Previous data demonstrated an independent role for the reduction or loss of pRb2/p130 expression in the formation and/or progression of lung carcinoma. Rb2/p130 is mutated in a human cell line of lung small cell carcinoma as well as in primary lung tumors," scientists in the United States report.
"To identify potential pRb2/p130 target genes in an unbiased manner, we have utilized an adenovirus-mediated expression...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2003-12-04)
More Articles from Gene Therapy Weekly
- Cancer Metastasis
Gene therapy containing p53 combines with CDDP to arrest liver tumor growth - Gynecology
PTEN overexpression squashes the migration of ovarian cancer cells - Cancer Therapy
Real-time imaging depicts how TRAIL can treat tumors - Cardiology
Electroporation improves DNAzyme delivery to vascular tissue - Gene Transfer
A novel amplicon system identifies obstacles to new therapies - Genetic Engineering
ONYX-015 augments radiotherapy directed against thyroid cancer cells - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
